Rekombinanter PDCD1 (Pembrolizumab Biosimilar) Antikörper
Research Grade
Reaktivität: Human
ELISA
Wirt: Mammalian Cells
Monoclonal
unconjugated
Recombinant Antibody
-
- Target Alle PDCD1 (Pembrolizumab Biosimilar) Produkte
- PDCD1 (Pembrolizumab Biosimilar)
- Antikörpertyp
- Recombinant Antibody
- Reaktivität
- Human
-
Wirt
-
Mammalian Cells
- Expressionssystem
- Mammalian cells
-
Klonalität
- Monoklonal
-
Konjugat
- Dieser PDCD1 (Pembrolizumab Biosimilar) Antikörper ist unkonjugiert
-
Applikation
- ELISA
- Verwendungszweck
- Pembrolizumab Biosimilar - Anti-PD1 mAb
- Produktmerkmale
- Antibody Type: IgG4
- Aufreinigung
- Recombinant antibody expressed in mammalien cells and purified.
- Güteklasse
- Research Grade
- Isotyp
- IgG4
-
anti-PDCD1 (Pembrolizumab Biosimilar) antibody
Research Grade Reaktivität: Human FACS, ELISA Wirt: Humanized Monoclonal unconjugated Recombinant Antibody
-
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Buffer
- PBS pH 7.5
- Lagerung
- 4 °C,-20 °C
- Informationen zur Lagerung
- 4°C for short term, -20°C for long term
-
- Target
- PDCD1 (Pembrolizumab Biosimilar)
- Abstract
- PDCD1 (Pembrolizumab Biosimilar) Produkte
- Substanzklasse
- Biosimilar
- Hintergrund
-
Pembrolizumab
Pembrolizumab is a humanized (from mouse) monoclonal antibody that binds to, and blocks PD-1 located on lymphocytes. It is an anticancer medication used in the treatment of melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, urothelial cancer (cancer of the bladder and urinary tract) and renal cell carcinoma (kidney cancer).
-
Sie sind hier:
